Emmes Selected as CRO Partner for CARRA Registry and Biorepository
In a significant development in pediatric rheumatology research, Emmes, a prominent global contract research organization (CRO), has been appointed as the CRO partner for the Childhood Arthritis and Rheumatology Research Alliance (CARRA). This collaboration aims to propel the next generation of the CARRA Registry and Biorepository, enhancing the future of pediatric rheumatology research.
A Legacy of Experience
Emmes boasts nearly four decades of expertise in registry studies and has been part of some of the most complex pediatric research networks across the nation. This extensive background uniquely positions them to lead the CARRA Registry into a new era, providing comprehensive services such as scientific support, project management, data management, and clinical operations under a Functional Service Provider (FSP) model.
CARRA Registry Overview
The CARRA Registry stands as one of North America’s largest and most enduring pediatric rheumatology research resources. With 70 clinical sites extending across the United States and Canada, the registry includes over 16,000 participants dealing with various pediatric rheumatic diseases, including juvenile idiopathic arthritis (JIA), lupus, juvenile dermatomyositis (JDM), and scleroderma. Importantly, the registry plays a critical role in investigating the safety, effectiveness, and long-term outcomes of treatments designed for children suffering from these conditions.
Evolving Research Landscape
This partnership marks a pivotal transition for the CARRA Registry as it enters a new hybrid operating model. The primary objectives include broadening site participation, modernizing data capture processes, and fortifying the infrastructure for both CARRA-led studies and biopharmaceutical-sponsored research. Emmes is set to assist CARRA in facilitating a smooth transition to this innovative operational framework, ensuring the continuous functioning of the registry while enhancing its support structures.
Commitment to Pediatric Health
Rachel Myslinski, CEO of CARRA, emphasized the strategic importance of this collaboration. She stated, “With Emmes as our next generation Registry Biorepository partner, we are well positioned to continue research that improves the lives of children with rheumatic disease.” Emmes’s extensive registry experience and collaborative mentality will undoubtedly contribute to turning years of data into actionable insights that can expedite the diagnostic journey and development of new therapies.
Furthermore, Paul VanVeldhuisen, Chief Scientific Officer at Emmes, expressed his gratitude for the opportunity, stating, “We are honored to be selected as CARRA's partner for the next generation of the Registry Biorepository.” This partnership reaffirms Emmes's commitment to advancing public health and fostering innovation in biopharmaceutical research.
Enhancing Clinical Capabilities
Within the scope of this partnership, Emmes will also introduce targeted support for CARRA’s biopharmaceutical partners, focusing on studies that utilize the CARRA Registry data. This will augment the registry’s flexibility and capabilities, enabling it to effectively support industry-sponsored research in pediatric rheumatic diseases.
About CARRA
CARRA, a nonprofit entity recognized under section 501(c)(3), thrives on its mission to consolidate the pediatric rheumatology community to drive impactful research. Since its inception in 2002, it has evolved into a collaborative research network on a continental scale and continues to maintain the CARRA Registry as a robust source of longitudinal data on pediatric rheumatic disease outcomes.
About Emmes
Founded in 1977, Emmes is a full-service CRO dedicated to advancing public health and biopharmaceutical innovation. With more than 2,000 clinical studies and registries under its belt, Emmes has a proven track record of supporting substantial pediatric patient registries and strives to continue enhancing the clinical research landscape. More information can be found at
www.emmes.com.
This strategic alliance marks a crucial step towards a deeper understanding and improved treatment options for pediatric rheumatic diseases, promising brighter futures for affected children and their families.